Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Evommune, Inc.NYSE: EVMN
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 25.7% from a year ago
Other current assets stood at $4.39M at the end of Q1 FY2026, down 25.7% from a year earlier and up 2.6% from the prior quarter.
Context
- Other current assets amounted to 1.4% of total assets at the end of Q1 FY2026, down 9.2 pp from a year earlier.
- Other current assets increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -25.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.28M USD
- Year-over-year change
- +119.6%
- 2-year CAGR
- +112.4%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.28M | +119.6% |
| FY2024 | 2024-12-31 | 1.95M | +105.5% |
| FY2023 | 2023-12-31 | 948K | — |
Other Current Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 other current assets of $4.39M is the 5th highest of the 10 companies compared; the peer median is $3.84M.
- Its year-over-year change of -25.7% is the 5th highest of 10, against a peer median of -27.9%.
- Other current assets amounts to 1.4% of total assets for EVMN, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $100.6M | -27.9% | -9.5% | 3.7% |
| Mar 2026 | $24.55M | +1652.5% | +195.1% | 8.5% | |
| Jun 2026 | $19.17M | -52.1% | +132.7% | 0.9% | |
| Mar 2026 | $8.53M | -17.1% | -24.0% | 6.5% | |
EVMNEvommune, Inc. | Mar 2026 | $4.39M | -25.7% | — | 1.4% |
CLYMClimb Bio, Inc. | Mar 2026 | $3.84M | +3268.4% | +16.6% | 2.5% |
| Mar 2026 | $3.41M | -2.6% | -15.0% | 1.2% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $1.36M | -54.8% | +33.9% | 1.3% |
| Mar 2026 | $400K | -91.4% | +126.6% | 0.3% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding EVMN) | $3.84M | -27.9% | +25.3% | 1.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.